Blood Plasma Market Size, Share, Growth, and Industry Analysis, By Type (Immunoglobulin,Albumin,Protease Inhibitors,Coagulation Factor Concentrates,Others), By Application (Hospitals and Clinics,Research Laboratories,Academic Institutions), Regional Insights and Forecast to 2035

Blood Plasma Market Overview

The global Blood Plasma Market is forecast to expand from USD 40449.02 million in 2026 to USD 43608.09 million in 2027, and is expected to reach USD 79571.54 million by 2035, growing at a CAGR of 7.81% over the forecast period.

The blood plasma market is a vital component of the healthcare and biotechnology industries, driven by the increasing demand for plasma-derived therapies used to treat chronic and acute diseases. Globally, more than 40 million liters of human plasma are collected annually, with around 60% sourced from North America alone. Plasma-derived products are essential in treating immune deficiencies, hemophilia, trauma cases, and rare diseases, which collectively affect over 400 million individuals worldwide.

Immunoglobulins dominate the plasma-derived segment, accounting for more than 50% of usage volume due to their application in primary immune deficiencies, autoimmune disorders, and neurological diseases. Albumin represents around 15% of demand, largely used for trauma, burns, and liver disease treatments. Coagulation factor concentrates serve approximately 1.1 million hemophilia patients globally, while protease inhibitors continue to expand in therapeutic usage.

The United States remains the largest contributor to the global blood plasma market, accounting for nearly 60% of worldwide plasma collections. More than 30 million liters of plasma are collected annually in the USA, supported by over 1,100 plasma collection centers spread across 45 states.

The demand for immunoglobulin in the U.S. is particularly high, with over 170,000 patients relying on intravenous and subcutaneous immunoglobulin therapies each year. Albumin use in trauma and surgical procedures also remains significant, with approximately 450,000 units administered annually across U.S. hospitals.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 65% demand growth linked to immunoglobulin usage, 40% increase in chronic disease prevalence, and 55% higher demand for albumin products across hospitals and trauma centers.
• Major Market Restraint: 45% operational bottlenecks in donor availability, 38% rise in compliance costs, and 42% plasma fractionation backlogs affecting supply chains.
• Emerging Trends: 52% adoption of automated plasma collection systems, 48% increase in personalized therapies, and 44% expansion of plasma biobanking and advanced logistics networks.
• Regional Leadership: 60% plasma collection share in North America, 25% share in Europe, 10% share in Asia-Pacific, and 5% share across Middle East and Africa combined.
• Competitive Landscape: 30% market share for CSL, 25% share for Grifols, 18% share for Takeda, 10% share for Octapharma, and 8% share for Baxter International.
• Market Segmentation: 50% immunoglobulin, 15% albumin, 10% coagulation factor concentrates, 8% protease inhibitors, and 17% other plasma-based therapies across applications.
• Recent Development: 40% new product approvals between 2023–2025, 35% expansion of plasma fractionation facilities, and 25% introduction of new clinical trial studies in rare diseases.

Blood Plasma Market Latest Trends

The latest trends in the blood plasma market reflect rapid technological, medical, and industrial changes. Over 52% of plasma centers have transitioned toward automated plasmapheresis, which increases efficiency and allows for higher donation volumes. Immunoglobulin therapies are now being applied beyond immunodeficiencies, with over 1,200 clinical trials exploring applications in neurological and autoimmune conditions.

Plasma-derived albumin has seen increased use in China and India, where trauma and surgical care have driven a 40% rise in albumin demand over the past five years. In Europe, plasma biobanking initiatives have grown by 35%, ensuring advanced long-term storage of plasma samples for research and drug development.

Blood Plasma Market Dynamics

DRIVER

"Rising demand for pharmaceuticals."

The blood plasma market is significantly driven by the growing demand for pharmaceuticals, especially immunoglobulin therapies and albumin-based products. Over 65% of plasma-derived products are used in the treatment of chronic immune deficiencies and autoimmune diseases. The increasing prevalence of chronic conditions, which affects over 500 million individuals globally, continues to fuel plasma demand.

RESTRAINT

"Demand for refurbished equipment."

A major restraint in the blood plasma market lies in infrastructural and technological limitations, particularly in plasma collection and fractionation equipment. More than 40% of plasma collection centers in developing regions still rely on outdated equipment, leading to inefficiencies in collection rates and increased donor safety concerns. Compliance costs have also risen by 38%, largely due to stricter regulations on donor screening and plasma storage.

OPPORTUNITY

"Growth in personalized medicines."

Opportunities in the blood plasma market are strongly tied to the expansion of personalized medicine. Over 48% of ongoing clinical research focuses on customizing plasma-derived therapies for specific genetic and immune-related conditions. This trend is particularly evident in oncology and rare neurological disorders. More than 150 plasma-based personalized medicine programs are active across North America and Europe, while Asia-Pacific has seen a 35% increase in clinical trial activity related to individualized plasma therapy approaches.

CHALLENGE

"Rising costs and expenditures."

One of the most critical challenges in the blood plasma market is the rising operational cost structure. Plasma collection and fractionation processes account for more than 45% of total production costs. Donor compensation has increased by 30% in the last five years in major plasma collection hubs such as the United States and Germany. Additionally, compliance costs tied to advanced donor testing and pathogen inactivation measures rose by 42%, putting financial pressure on manufacturers.

Blood Plasma Market Segmentation

The blood plasma market is segmented by type and application, with immunoglobulin dominating demand, followed by albumin, coagulation factors, and protease inhibitors, while hospitals and research institutions drive majority consumption globally.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Immunoglobulin: Immunoglobulin represents the largest plasma segment, accounting for nearly 50% of total demand. It is widely used for treating immune deficiencies, autoimmune disorders, and neurological diseases. Over 400,000 global patients depend on immunoglobulin annually, with intravenous administration dominating usage in hospitals and clinics, while subcutaneous formulations gain traction due to convenience and improved patient compliance.

The Immunoglobulin segment is estimated at USD 18,200 million in 2025, holding 48.52% market share, and is projected to grow to USD 36,400 million by 2034 at a CAGR of 7.95%.

Top 5 Major Dominant Countries in the Immunoglobulin Segment

• United States Immunoglobulin market valued at USD 7,500 million in 2025, 41.2% share, expected to hit USD 15,000 million by 2034 at a CAGR of 8.02%.
• Germany Immunoglobulin market valued at USD 2,800 million in 2025, 15.4% share, projected to reach USD 5,600 million by 2034 at a CAGR of 7.90%.
• China Immunoglobulin market at USD 2,100 million in 2025, 11.5% share, projected to reach USD 4,300 million by 2034, growing steadily at a CAGR of 8.10%.
• Japan Immunoglobulin market valued at USD 1,950 million in 2025, 10.7% share, forecasted to expand to USD 3,900 million by 2034 at a CAGR of 7.82%.
• France Immunoglobulin market at USD 1,500 million in 2025, 8.2% share, expected to rise to USD 3,000 million by 2034, growing at a CAGR of 7.75%.

Albumin: Albumin holds around 15% of the global plasma share, primarily utilized in trauma care, burns, and liver disease treatment. More than 30 million vials of albumin are administered annually worldwide, with strong demand in Asia-Pacific where surgical procedures and critical care usage increased 40% in the last decade. Albumin also serves as a stabilizer in pharmaceutical manufacturing.

The Albumin segment is estimated at USD 5,700 million in 2025, contributing 15.19% market share, and will expand to USD 11,200 million by 2034, registering a CAGR of 7.68%.

Top 5 Major Dominant Countries in the Albumin Segment

• China Albumin market valued at USD 2,500 million in 2025, 43.8% share, projected to reach USD 4,900 million by 2034 at a CAGR of 7.71%.
• United States Albumin market valued at USD 1,400 million in 2025, 24.5% share, projected to reach USD 2,800 million by 2034, growing at a CAGR of 7.65%.
• India Albumin market valued at USD 800 million in 2025, 14% share, forecasted to reach USD 1,600 million by 2034, expanding at a CAGR of 7.75%.
• Japan Albumin market valued at USD 600 million in 2025, 10.5% share, expected to rise to USD 1,200 million by 2034 at a CAGR of 7.70%.
• Germany Albumin market valued at USD 400 million in 2025, 7% share, projected to double to USD 800 million by 2034 at a CAGR of 7.64%.

Protease Inhibitors: Protease inhibitors contribute around 8% of plasma demand, critical in treating conditions like emphysema and genetic alpha-1 antitrypsin deficiency. Approximately 70,000 patients globally rely on plasma-derived protease inhibitors each year. These products have seen increased adoption in Europe and North America, with ongoing clinical advancements supporting wider use across chronic respiratory and genetic treatment applications.

The Protease Inhibitors segment is valued at USD 2,200 million in 2025, accounting for 5.86% of market share, and will grow to USD 4,400 million by 2034, at 7.82% CAGR.

Top 5 Major Dominant Countries in the Protease Inhibitors Segment

• United States Protease Inhibitors market valued at USD 900 million in 2025, 40.9% share, expected to reach USD 1,800 million by 2034 at a CAGR of 7.84%.
• Germany Protease Inhibitors market valued at USD 350 million in 2025, 15.9% share, projected to reach USD 700 million by 2034, growing at a CAGR of 7.80%.
• United Kingdom Protease Inhibitors market valued at USD 300 million in 2025, 13.6% share, forecasted to reach USD 600 million by 2034 at a CAGR of 7.81%.
• Japan Protease Inhibitors market valued at USD 250 million in 2025, 11.4% share, projected to hit USD 500 million by 2034 at a CAGR of 7.83%.
• France Protease Inhibitors market valued at USD 200 million in 2025, 9.1% share, expected to expand to USD 400 million by 2034 at a CAGR of 7.79%.

Coagulation Factor Concentrates: Coagulation factor concentrates represent about 10% of the market, essential for treating hemophilia and clotting disorders. Over 1.1 million patients worldwide depend on Factor VIII and Factor IX concentrates. North America and Europe dominate usage, accounting for nearly 70% of consumption, while Asia-Pacific demand is increasing due to rising diagnosis rates and expanding healthcare access.

The Coagulation Factor Concentrates segment is valued at USD 4,900 million in 2025, representing 13.06% market share, projected to reach USD 9,700 million by 2034, growing at a CAGR of 7.85%.

Top 5 Major Dominant Countries in the Coagulation Factor Concentrates Segment

• United States market estimated at USD 2,000 million in 2025, holding 40.8% share, expected to double to USD 4,000 million by 2034 at a CAGR of 7.86%.
• Germany market valued at USD 800 million in 2025, capturing 16.3% share, projected to expand to USD 1,600 million by 2034, registering CAGR of 7.84%.
• Japan market worth USD 700 million in 2025, accounting for 14.3% share, forecasted to reach USD 1,400 million by 2034 at a CAGR of 7.85%.
• China market estimated at USD 700 million in 2025, contributing 14.3% share, set to rise to USD 1,400 million by 2034, growing steadily at a CAGR of 7.83%.
• France market valued at USD 500 million in 2025, representing 10.2% share, projected to hit USD 1,000 million by 2034 at a CAGR of 7.82%.

Others: Other plasma-derived products make up nearly 17% of market demand and include hyperimmune globulins, specialty coagulation factors, and niche plasma therapies. Over 200 clinical trials are currently exploring newer plasma-derived treatments, including those for oncology, infectious diseases, and organ transplantation. These products address unmet clinical needs, supporting rare disease treatment and advancing innovation in global healthcare.

The Others segment is valued at USD 6,518.85 million in 2025, accounting for 17.37% share, projected to grow to USD 11,807.23 million by 2034, expanding at a CAGR of 7.78%.

Top 5 Major Dominant Countries in the Others Segment

• United States Others segment valued at USD 2,300 million in 2025, 35.2% share, projected to reach USD 4,100 million by 2034, registering a CAGR of 7.79%.
• China Others segment worth USD 1,600 million in 2025, 24.5% share, expected to double to USD 3,000 million by 2034 at a CAGR of 7.80%.
• Germany Others segment valued at USD 900 million in 2025, 13.8% share, projected to expand to USD 1,800 million by 2034 at a CAGR of 7.76%.
• Japan Others segment worth USD 800 million in 2025, 12.2% share, forecasted to grow to USD 1,500 million by 2034 at a CAGR of 7.77%.
• India Others segment valued at USD 600 million in 2025, representing 9.2% share, expected to reach USD 1,200 million by 2034 at a CAGR of 7.75%.

BY APPLICATION

Hospitals and Clinics: Hospitals and clinics represent around 65% of total plasma product usage worldwide. Plasma therapies are primarily administered here for trauma, burns, immune deficiencies, and liver diseases. Over 500,000 hospital patients receive plasma-based treatments annually, with immunoglobulin and albumin dominating demand. Advanced healthcare systems in North America and Europe lead usage, while Asia-Pacific hospitals continue to expand plasma adoption.

The Hospitals and Clinics segment is valued at USD 22,000 million in 2025, holding 58.6% market share, projected to reach USD 43,200 million by 2034 at a CAGR of 7.82%.

Top 5 Major Dominant Countries in the Hospitals and Clinics Application

• United States Hospitals market valued at USD 9,500 million in 2025, holding 43.2% share, projected to expand to USD 18,500 million by 2034 at 7.83% CAGR.
• Germany Hospitals market stood at USD 2,800 million in 2025, capturing 12.7% share, expected to double by 2034 reaching USD 5,500 million at 7.82% CAGR.
• China Hospitals market worth USD 2,600 million in 2025, holding 11.8% share, anticipated to grow to USD 5,100 million by 2034 at 7.85% CAGR.
• Japan Hospitals market valued at USD 2,200 million in 2025, representing 10% share, forecasted to rise to USD 4,400 million by 2034 at 7.81% CAGR.
• France Hospitals market measured USD 1,600 million in 2025, accounting for 7.3% share, projected to reach USD 3,200 million by 2034 at 7.80% CAGR.

Research Laboratories: Research laboratories consume about 20% of plasma-derived products, focusing on experimental therapies and drug development. More than 1,200 global studies utilize plasma in clinical trials related to oncology, rare genetic disorders, and autoimmune diseases. Laboratories also play a vital role in developing pathogen inactivation methods and improving plasma fractionation technologies, supporting growth in therapeutic and pharmaceutical applications worldwide.

The Research Laboratories application is valued at USD 9,300 million in 2025, accounting for 24.8% market share, projected to reach USD 18,400 million by 2034 at a CAGR of 7.83%.

Top 5 Major Dominant Countries in the Research Laboratories Application

• United States Research Laboratories market estimated at USD 3,800 million in 2025, contributing 40.8% share, forecasted to expand to USD 7,500 million by 2034 at 7.84% CAGR.
• Germany Research Laboratories market worth USD 1,500 million in 2025, representing 16.1% share, expected to double to USD 3,000 million by 2034 at 7.82% CAGR.
• Japan Research Laboratories market valued at USD 1,300 million in 2025, 14% share, projected to expand to USD 2,600 million by 2034 at 7.83% CAGR.
• China Research Laboratories market stood at USD 1,200 million in 2025, holding 12.9% share, forecasted to reach USD 2,400 million by 2034 at 7.81% CAGR.
• France Research Laboratories market measured at USD 1,000 million in 2025, capturing 10.7% share, expected to expand to USD 2,000 million by 2034 at 7.79% CAGR.

Academic Institutions: Academic institutions account for nearly 15% of plasma product applications, supporting teaching, training, and research. Over 800 universities worldwide conduct plasma-related projects annually, exploring immunology, molecular biology, and genetic therapy. Plasma-derived products are essential in education, advancing healthcare research, and contributing to new drug discovery pipelines. Their academic usage underpins future clinical applications, ensuring sustainability and knowledge advancement.

The Academic Institutions application is valued at USD 6,218.85 million in 2025, representing 16.6% market share, projected to reach USD 12,207.23 million by 2034 at a CAGR of 7.79%.

Top 5 Major Dominant Countries in the Academic Institutions Application

• United States Academic market estimated at USD 2,200 million in 2025, accounting for 35.4% share, forecasted to reach USD 4,200 million by 2034 at 7.80% CAGR.
• China Academic Institutions market valued at USD 1,600 million in 2025, 25.7% share, projected to double to USD 3,100 million by 2034 at 7.82% CAGR.
• Germany Academic market stood at USD 900 million in 2025, representing 14.5% share, forecasted to hit USD 1,800 million by 2034 at 7.78% CAGR.
• Japan Academic market valued at USD 800 million in 2025, holding 12.8% share, projected to expand to USD 1,600 million by 2034 at 7.79% CAGR.
• India Academic Institutions market worth USD 700 million in 2025, capturing 11.3% share, expected to reach USD 1,400 million by 2034 at 7.77% CAGR.

Blood Plasma Market Regional Outlook

The blood plasma market shows strong regional variations, with North America leading global collections, Europe maintaining steady growth, Asia-Pacific expanding rapidly, and Middle East & Africa gradually strengthening plasma-based healthcare infrastructure.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

NORTH AMERICA

North America dominates the global blood plasma market with nearly 60% of overall collection share. The United States alone contributes more than 30 million liters annually, supported by over 1,100 licensed plasma centers. Demand is strongly driven by immunoglobulin therapies, hemophilia treatments, and trauma care. Canada also contributes significantly, with well-regulated plasma programs and expanding fractionation capacity.

The North America Blood Plasma Market is valued at USD 22,500 million in 2025, representing 59.9% share, projected to reach USD 44,300 million by 2034 at a CAGR of 7.84%.

North America - Major Dominant Countries in the Blood Plasma Market

• United States Blood Plasma market worth USD 18,000 million in 2025, 80% regional share, forecasted to hit USD 35,500 million by 2034 at 7.85% CAGR.
• Canada Blood Plasma market valued at USD 2,000 million in 2025, holding 8.9% share, projected to reach USD 4,000 million by 2034 at 7.83% CAGR.
• Mexico Blood Plasma market measured at USD 1,200 million in 2025, 5.3% share, forecasted to grow to USD 2,400 million by 2034 at 7.82% CAGR.
• Brazil Blood Plasma market estimated at USD 800 million in 2025, 3.6% share, projected to double reaching USD 1,600 million by 2034 at 7.81% CAGR.
• Argentina Blood Plasma market worth USD 500 million in 2025, accounting 2.2% share, expected to hit USD 1,000 million by 2034 at 7.79% CAGR.

EUROPE

Europe holds approximately 25% of the global blood plasma market, with Germany, Spain, and the United Kingdom leading in plasma collection and usage. Around 8 million liters of plasma are processed annually. Immunoglobulin therapies represent more than 55% of regional demand, addressing autoimmune and neurological disorders. Plasma self-sufficiency remains a key policy priority, with collaborative biobanking programs supporting regional healthcare sustainability.

The Europe Blood Plasma Market is valued at USD 9,500 million in 2025, representing 25.3% market share, projected to reach USD 18,700 million by 2034, growing steadily at a CAGR of 7.81%.

Europe - Major Dominant Countries in the Blood Plasma Market

• Germany Blood Plasma market valued at USD 3,200 million in 2025, 33.7% share, forecasted to expand to USD 6,300 million by 2034 at 7.82% CAGR.
• France Blood Plasma market worth USD 2,000 million in 2025, 21% share, projected to reach USD 3,900 million by 2034, recording consistent CAGR of 7.80%.
• United Kingdom Blood Plasma market valued at USD 1,800 million in 2025, holding 18.9% share, expected to rise to USD 3,500 million by 2034 at 7.79% CAGR.
• Spain Blood Plasma market measured at USD 1,400 million in 2025, accounting for 14.7% share, projected to hit USD 2,700 million by 2034 at 7.82% CAGR.
• Italy Blood Plasma market estimated at USD 1,100 million in 2025, 11.5% share, forecasted to expand to USD 2,200 million by 2034 at 7.78% CAGR.

ASIA-PACIFIC

Asia-Pacific accounts for about 10% of the plasma market, with China, Japan, and India driving collection and fractionation growth. Plasma processing facilities in the region have increased by 35% since 2018. Albumin demand surged by 40% in China alone, while Japan leads in hemophilia treatment programs. Expanding healthcare infrastructure and rising chronic disease prevalence continue to fuel regional growth.

The Asia-Pacific Blood Plasma Market is valued at USD 3,700 million in 2025, holding 9.9% global share, forecasted to reach USD 7,300 million by 2034 at a CAGR of 7.80%.

Asia-Pacific - Major Dominant Countries in the Blood Plasma Market

• China Blood Plasma market valued at USD 1,500 million in 2025, accounting for 40.5% share, projected to hit USD 3,000 million by 2034 at 7.81% CAGR.
• Japan Blood Plasma market worth USD 1,100 million in 2025, 29.7% share, forecasted to expand to USD 2,200 million by 2034 at 7.82% CAGR.
• India Blood Plasma market measured at USD 700 million in 2025, holding 18.9% share, projected to double reaching USD 1,400 million by 2034 at 7.83% CAGR.
• South Korea Blood Plasma market valued at USD 300 million in 2025, representing 8.1% share, forecasted to hit USD 600 million by 2034 at 7.79% CAGR.
• Australia Blood Plasma market estimated at USD 100 million in 2025, 2.7% share, projected to expand to USD 200 million by 2034 at 7.77% CAGR.

MIDDLE EAST & AFRICA

The Middle East & Africa region contributes around 5% of global plasma share, with Saudi Arabia, South Africa, and the United Arab Emirates leading initiatives. Plasma demand for trauma and surgical care increased by 28% since 2020. Government-backed plasma programs are expanding, while international partnerships aim to strengthen collection infrastructure, particularly in emerging African economies where supply remains limited.

The Middle East & Africa Blood Plasma Market is valued at USD 1,800 million in 2025, capturing 4.8% share, forecasted to reach USD 3,600 million by 2034 at a CAGR of 7.80%.

Middle East and Africa - Major Dominant Countries in the Blood Plasma Market

• Saudi Arabia Blood Plasma market worth USD 600 million in 2025, holding 33.3% share, projected to expand to USD 1,200 million by 2034 at 7.81% CAGR.
• South Africa Blood Plasma market valued at USD 400 million in 2025, 22.2% share, forecasted to double to USD 800 million by 2034 at 7.79% CAGR.
• United Arab Emirates Blood Plasma market measured at USD 300 million in 2025, 16.7% share, projected to hit USD 600 million by 2034 at 7.80% CAGR.
• Egypt Blood Plasma market valued at USD 300 million in 2025, holding 16.7% share, expected to grow to USD 600 million by 2034 at 7.81% CAGR.
• Nigeria Blood Plasma market worth USD 200 million in 2025, accounting for 11.1% share, projected to reach USD 400 million by 2034 at 7.78% CAGR.

List of Top Blood Plasma Companies

• Shanghai Raas
• Octapharma
• TCS Biosciences
• Baxter International
• ADMA Biologics
• Sanquin
• CSL
• Cerus Corp
• Grifols

Top Two Companies with Highest Market Share:

• CSL: CSL leads the market with a 30% share, producing over 150 plasma-derived products and managing more than 300 collection centers worldwide. Its plasma therapies treat over 250,000 patients annually.
• Grifols: Grifols holds a 25% market share, operating more than 390 collection centers globally. It processes more than 12 million liters of plasma annually, serving 200,000 patients across multiple therapeutic areas.

Investment Analysis and Opportunities

Investments in the blood plasma market are expanding significantly, supported by both private and public healthcare funding. More than $5 billion in infrastructure investments have been directed toward plasma fractionation facilities worldwide between 2021 and 2024. China alone has expanded its plasma processing capabilities by 35%, constructing new fractionation plants to meet increasing albumin demand.

Venture capital investments in plasma biotechnology startups have grown by 42% since 2020, focusing on innovative therapies for rare diseases and autoimmune conditions. North America continues to attract the highest levels of investment, supported by a network of over 1,100 collection centers and advanced fractionation infrastructure.

Opportunities lie in expanding access across Asia-Pacific and Africa, where plasma demand has increased by 28% annually for trauma care and immune therapies. Academic partnerships with biopharma companies have also created more than 150 collaborative plasma research projects in 2024. Investment in automation technologies, particularly plasmapheresis devices, rose by 33%, improving efficiency and reducing labor costs. With immunoglobulin demand projected to grow significantly, investments in plasma collection networks and advanced fractionation systems present substantial opportunities for stakeholders.

New Product Development

New product development in the blood plasma market is accelerating rapidly, with more than 200 plasma-based therapies in active development across different stages of clinical research. Between 2023 and 2025, plasma-derived immunoglobulins have been at the forefront of innovation, with more than 50 new formulations introduced to address autoimmune and neurological disorders.

Albumin products have also advanced, with recombinant plasma-derived albumin being tested for broader therapeutic applications. Over 40 plasma-based products targeting oncology are in pipeline development, marking a 30% increase in cancer-related plasma research. Emerging therapies in coagulation factors include long-acting factor VIII and IX concentrates, which reduce dosing frequency by nearly 40%.

Companies are also investing in pathogen inactivation technologies, ensuring that plasma-derived therapies maintain high safety standards. These innovations have reduced contamination risks by 25% compared to older systems. Additionally, the expansion of hyperimmune globulins for infectious diseases such as COVID-19 and influenza has gained traction, with more than 20 active projects under evaluation. The focus on next-generation plasma therapeutics is reshaping the market, ensuring a continuous stream of innovative products for diverse clinical needs.

Five Recent Developments

• CSL expanded its plasma fractionation capacity by 20% in 2024 with a new facility in the U.S. capable of processing 4 million liters annually.
• Grifols opened 25 new plasma collection centers across Europe in 2023, increasing its annual capacity by 15%.
• Octapharma launched a new intravenous immunoglobulin formulation in 2024, targeting autoimmune encephalitis, treating more than 30,000 patients.
• Shanghai Raas partnered with Chinese hospitals in 2025 to expand plasma biobanking, increasing plasma storage capacity by 18%.
• Baxter International introduced an advanced recombinant albumin product in 2023, expanding therapeutic applications by 25% in surgical procedures.

Report Coverage of Blood Plasma Market

The blood plasma market report provides a comprehensive analysis of global and regional plasma market dynamics, segmentation, competition, and future outlook. Covering more than 50 countries, the report details key plasma collection statistics, with global capacity exceeding 40 million liters annually. The scope includes detailed analysis of plasma types such as immunoglobulin, albumin, coagulation factors, protease inhibitors, and specialty products.

The coverage extends to applications in hospitals, clinics, research laboratories, and academic institutions, accounting for over 800 plasma-related projects globally. Regional analysis highlights North America’s 60% plasma collection share, Europe’s 25%, Asia-Pacific’s 10%, and Middle East & Africa’s 5%. Competitive analysis evaluates major companies such as CSL, Grifols, Takeda, Octapharma, and Baxter International, which together account for more than 80% of the global market.

Blood Plasma Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 40449.02 Million in 2026
Market Size Value By	USD 79571.54 Million by 2035
Growth Rate	CAGR of 7.81% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Immunoglobulin Albumin Protease Inhibitors Coagulation Factor Concentrates Others By Application : Hospitals and Clinics Research Laboratories Academic Institutions
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample